Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Lewis

Interventional Cardiology Maywood, IL Medical Doctor

NPI 1538238050 CMS profile 24493

2160 S First Ave, (17W740 22Nd Street, Oakbrook Terrace, Il. 60181), Maywood, IL 60153

Open in the dashboard

General payments

$82,763

313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,233,868 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Bruce Lewis of Maywood, IL is reported in the CMS Open Payments database as having received $82,763 across 313 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,233,868 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,566 27
2024 General $1,851 48
2023 General $1,323 33
2022 General $16,456 60
2021 General $8,395 50
2020 General $11,837 42
2019 General $41,335 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Lewis
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Bruce Lewis were reported at $1,566. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Bruce Lewis Interventional Cardiology median Middle half National median
2019 $41,335 $1,097 $329–$3,048 $163
2020 $11,837 $473 $161–$1,480 $114
2021 $8,395 $677 $233–$1,827 $132
2022 $16,456 $978 $333–$2,724 $149
2023 $1,323 $1,136 $382–$2,986 $160
2024 $1,851 $1,181 $395–$3,326 $164
2025 $1,566 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $72,561 103 payments
  2. Abbott Laboratories $2,577 49 payments
  3. Medtronic, Inc. $1,305 24 payments
  4. Biotronik Inc. $1,179 26 payments
  5. Esperion Therapeutics, Inc. $634 14 payments
  6. Edwards Lifesciences Corporation $605 6 payments
  7. Novartis Pharmaceuticals Corporation $510 19 payments
  8. Medtronic Vascular, Inc. $488 6 payments
  9. Lilly USA, LLC $450 1 payment
  10. Cardiovascular Systems Inc. $366 8 payments
  11. Other $2,089 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,990 27 payments
  2. Food and Beverage $11,327 267 payments
  3. Travel and Lodging $1,515 4 payments
  4. Education $631 14 payments
  5. Consulting Fee $300 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $72,561 103 payments
  2. NEXLETOL $634 14 payments
  3. SAPIEN 3 Ultra RESILIA $605 6 payments
  4. MitraClip System $572 7 payments
  5. SYMPLICITY G3 $541 6 payments
  6. MITRACLIP Structural Heart $513 9 payments
  7. MITRACLIP Vascular $513 13 payments
  8. EFFIENT $450 1 payment
  9. PK Papyrus $428 9 payments
  10. Orsiro Mission $420 7 payments
  11. Other $7,389 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

11,608

Median for Interventional Cardiology: 2,236

Drug cost

$2,000,892

Median for Interventional Cardiology: $380,412

Branded share of claims

30.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 506 $550,279
Eliquis Apixaban Brand 447 $488,176
Repatha Sureclick Evolocumab Brand 261 $217,750
Jardiance Empagliflozin Brand 188 $194,967
Entresto Sacubitril/Valsartan Brand 126 $155,152
Multaq Dronedarone Hcl Brand 42 $73,167
Farxiga Dapagliflozin Propanediol Brand 60 $56,688
Praluent Pen Alirocumab Brand 39 $48,830
Ozempic Semaglutide Brand 12 $24,039
Brilinta Ticagrelor Brand 13 $17,144

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$476,320

Medicare's payments for the services billed

Medicare patients

1,549

Average age 77

Services billed

3,998

684 women, 865 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 52%
Heart failure 42%
Diabetes 39%
Atrial fibrillation 38%
Chronic kidney disease 31%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $75
$75 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $75
$75 126 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $63
$63 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $49
$49 60 —
NEXLETOL
  • Esperion Therapeutics, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record